At this time early research in general shows the plus side of these medications outweighs some potential side effects. In this The risk of diabetic retinopathy came with the results of the SUSTAIN 6 trial, the first that compared the effect of semaglutide in cardiovascular outcomes in subjects with type 2 diabetes, Fernando Gerchman, MD, PhD, professor of medicine in the Division of Endocrinology and Metabolism at the Hospital de Clnicas de Porto Alegre in Brazil and senior author of this study, told MNT
In this series of videos he explains the benefits of new FDA approved medications and their side effects.
The life-course of PA development has not been studied, but there is sufficient information to highlight that the timelines are highly varied among patients
The studies, which provide new results from two clinical trials, compared the effects of semaglutide versus placebo in reducing heart failure-related symptoms, physical limitations, weight and heart failure hospitalizations in patients with obesity and heart failure with preserved ejection fraction, or HFpEF
